Combination regimens in EGFR-mutated lung cancer: Can we get ORIENT-ed? Editorial


Authors: Elkrief, A.; Yu, H.
Title: Combination regimens in EGFR-mutated lung cancer: Can we get ORIENT-ed?
Keywords: cancer survival; gene mutation; overall survival; genetics; mutation; bevacizumab; cisplatin; drug efficacy; note; gene; progression free survival; protein kinase inhibitor; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; lung cancer; protein kinase inhibitors; lung tumor; lung metastasis; platinum derivative; egfr gene; pemetrexed; egfr protein, human; non small cell lung cancer; erbb receptors; humans; human; osimertinib; atezolizumab; sintilimab
Journal Title: Lancet Oncology
Volume: 23
Issue: 9
ISSN: 1470-2045
Publisher: Elsevier Science, Inc.  
Date Published: 2022-09-01
Start Page: 1113
End Page: 1114
Language: English
DOI: 10.1016/s1470-2045(22)00449-1
PUBMED: 35908559
PROVIDER: scopus
DOI/URL:
Notes: Note -- Export Date: 3 October 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Helena Alexandra Yu
    292 Yu
  2. Arielle Elkrief
    43 Elkrief